United States
|
|
| Product Center | |
 BBL™ MGIT™ PANTA™ Antibiotic Mixture, Lyophilized |
|
| Cat. # | Desc. | Qty. | Unit |
| 245114 | BBL™ MGIT™ PANTA™ Antibiotic Mixture, Lyophilized | 6 | SP |
The BBL™ MGIT™ Mycobacteria Growth Indicator Tube supplemented with BBL™ MGIT™ OADC enrichment and BBL™ MGIT™ PANTA™ antibiotic mixture, when appropriate, is intended for the detection and recovery of mycobacteria. Acceptable specimen types are digested and decontaminated clinical specimens (except urine) and sterile body fluids (except blood).
| Catalog # | Description | Quantity | Unit |
| 245114 | BBL™ MGIT™ PANTA™ Antibiotic Mixture, Lyophilized | 6 | SP |
The BBL™ MGIT™ Mycobacteria Growth Indicator Tube supplemented with BBL™ MGIT™ OADC enrichment and BBL™ MGIT™ PANTA™ antibiotic mixture, when appropriate, is intended for the detection and recovery of mycobacteria. Acceptable specimen types are digested and decontaminated clinical specimens (except urine) and sterile body fluids (except blood). The BBL™ MGIT™ Mycobacteria Growth Indicator Tube supplemented with BBL™ MGIT™ OADC enrichment and BBL™ MGIT™ PANTA™ antibiotic mixture, when appropriate, is intended for the detection and recovery of mycobacteria. Acceptable specimen types are digested and decontaminated clinical specimens (except urine) and sterile body fluids (except blood). From 1985 to 1992, the number of MTB cases reported increased 18%. Tuberculosis still kills an estimated 3 million persons a year worldwide, making it the leading infectious disease cause of death.1 Between 1981 and 1987, AIDS case surveillances indicated that 5.5% of the patients with AIDS had disseminated nontuberculous mycobacterial infections, e.g., MAC. By 1990, the increased cases of disseminated nontuberculous mycobacterial infections had resulted in a cumulative incidence of 7.6%.2 In addition to the resurgence of MTB, multidrug-resistant MTB (MDR-TB) has become an increasing concern. Laboratory delays in the growth, identification and reporting of these MDR-TB cases contributed at least in part to the spread of the disease.3 The U.S. Centers for Disease Control and Prevention (CDC) have recommended that every effort must be made by laboratories to use the most rapid methods available for diagnostic mycobacteria testing. These recommendations include the use of both a liquid and a solid medium for mycobacterial culture.3 The MGIT Mycobacteria Growth Indicator Tube contains 4 mL of modified Middlebrook 7H9 Broth base.4,5 The complete medium, with 0.5 mL OADC enrichment and 0.1 mL of PANTA antibiotic mixture, is one of the most commonly used liquid media for the cultivation of mycobacteria. All types of clinical specimens, pulmonary as well as extra-pulmonary (except blood and urine), can be processed for primary isolation in the MGIT tube using conventional methods.6 The processed specimen is inoculated into a MGIT tube, incubated and read daily from the second day of incubation using a longwave UV light. At the time of tube positivity, there are approximately 104 – 107 CFU/mL of mycobacteria present. From 1985 to 1992, the number of MTB cases reported increased 18%. Tuberculosis still kills an estimated 3 million persons a year worldwide, making it the leading infectious disease cause of death.1 Between 1981 and 1987, AIDS case surveillances indicated that 5.5% of the patients with AIDS had disseminated nontuberculous mycobacterial infections, e.g., MAC. By 1990, the increased cases of disseminated nontuberculous mycobacterial infections had resulted in a cumulative incidence of 7.6%.2 In addition to the resurgence of MTB, multidrug-resistant MTB (MDR-TB) has become an increasing concern. Laboratory delays in the growth, identification and reporting of these MDR-TB cases contributed at least in part to the spread of the disease.3 The U.S. Centers for Disease Control and Prevention (CDC) have recommended that every effort must be made by laboratories to use the most rapid methods available for diagnostic mycobacteria testing. These recommendations include the use of both a liquid and a solid medium for mycobacterial culture.3 The MGIT Mycobacteria Growth Indicator Tube contains 4 mL of modified Middlebrook 7H9 Broth base.4,5 The complete medium, with 0.5 mL OADC enrichment and 0.1 mL of PANTA antibiotic mixture, is one of the most commonly used liquid media for the cultivation of mycobacteria. All types of clinical specimens, pulmonary as well as extra-pulmonary (except blood and urine), can be processed for primary isolation in the MGIT tube using conventional methods.6 The processed specimen is inoculated into a MGIT tube, incubated and read daily from the second day of incubation using a longwave UV light. At the time of tube positivity, there are approximately 104 – 107 CFU/mL of mycobacteria present. Upon receipt of a new shipment or lot number of MGIT tubes, it is suggested that suspensions of the ATCC control organisms be prepared in Middlebrook 7H9 Broth. 1. From solid media cultures less than 15 days old, prepare a suspension in Middlebrook 7H9 Broth. The MGIT tubes should show fluorescence within the time frame shown in Table 1. Table 1
At the time of tube positivity, there are approximately 104 – 107 CFU/mL of mycobacteria present. If the QC MGIT tubes do not give the expected results, do not use the remaining tubes until you have contacted Technical Services at (800) 638-8663 (United States only). The BBL MGIT Mycobacteria Growth Indicator Tube contains: 110 µL of fluorescent indicator and 4 mL of broth. The indicator contains Tris 4, 7-diphenyl-1,10-phenanthroline ruthenium chloride pentahydrate in a silicone rubber base. The tubes are flushed with 10% CO2 and capped with polypropylene caps.
For in vitro Diagnostic Use. Pathogenic microorganisms including Hepatitis B Virus and Human Immunodeficiency Virus may be present in specimens. "Universal Precautions"1,2 should be followed in handling all items contaminated with blood or other body fluids. Working with Mycobacterium tuberculosis grown in culture requires Biosafety Level 3 practices, containment equipment and facilities.6 Prior to use, each MGIT tube should be examined for evidence of contamination or damage. Discard any tubes if they appear unsuitable or exhibit fluorescence prior to use. Dropped tubes should be examined carefully. If damage is seen, the tube should be discarded. Wear UV protective glasses when observing fluorescence and use only longwave illumination (365 nm). DO NOT USE SHORTWAVE UV LIGHT FOR READING TUBES. Autoclave all inoculated MGIT tubes prior to disposal. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Information shown on this page is a short summary extracted from the Package Insert, available as a PDF under the Related Documents section of this page.
